By. Stuart McIntosh, MD
Date. November 03, 2023
Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology. His work involved combining samuraciclib, a CDK7 inhibitor, with elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), specifically for patients with CDK4/6 inhibitor-resistant HR+, HER2- metastatic breast cancer.
The study aimed to address resistance to CDK4/6 inhibitors in this specific patient subset. McIntosh’s research sought to explore the benefits of this combination therapy, focusing on efficacy, safety, and tolerability.
The investigation explored the risks and benefits linked with the combination therapy. Early findings indicated potential therapeutic advantages in managing resistance in this patient group. However, risks associated with this novel treatment were carefully assessed.
McIntosh’s team conducted detailed assessments to understand the tolerability and pharmacokinetics of the combination, observing patient tolerance and drug interactions within the body to ensure safety and efficacy.
The trial involved a comprehensive analysis to evaluate longer-term progression-free survival benefits. Patients were tracked over an extended period to observe how the combination therapy affected disease progression and its potential for longer-term management.
Additionally, considering samuraciclib’s status as a first-in-class CDK7 inhibitor, McIntosh’s research team explored other potential therapeutic combinations for CDK4/6 inhibitor-resistant HR+, HER2- metastatic breast cancer, aiming for improved patient outcomes.
McIntosh’s commitment to this research marked a significant step in developing more effective treatments for this challenging form of breast cancer, offering hope to patients dealing with this difficult condition.